skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Saridegib (Code C80063)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Saridegib

Definition: An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Saridegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signaling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.

Display Name: Saridegib

Label: Saridegib

NCI Thesaurus Code: C80063 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2703211  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
IP9 Free Base
IPI-926 Free Base
Smoothened Antagonist IPI-926

External Source Codes: 
CAS Registry Number 1037210-93-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 616875
PDQ Open Trial Search ID 616875 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703211

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C29H48N2O3S
code C80063
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Smoothened_Antagonist_IPI-926
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom